Company profile
Avalo Therapeutics, Inc.
NASDAQ: AVTX · Healthcare · Biotechnology
#1079 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
41DFH 29DQ 67GM 17SS 59
v0.1 · 65/100 weight · provisional
↑ market scale, disclosure history · ↓ Piotroski F, operating margin
Methodology →Revenue TTM
$59.0k
Rev growth YoY (TTM)
-86.6%
Net income (FY)
-$78.3M
Employees
33
as of 2026-08-13
Market cap
$1.0B
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$59.0k$59.0k2025
Net income-$78.3M-$78.3M2025
Operating income-$72.9M-$72.9M2025
Total assets$116.5M$116.5M2025
Liabilities$33.4M$33.4M2025
Equity$83.0M$83.0M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product100%
By geography
Not disclosed.
The read
What is Avalo Therapeutics, Inc.’s revenue?
Avalo Therapeutics, Inc. booked $59.0k in FY2025 revenue, contracting 87% year over year — slower than 90% of Healthcare companies we track, at a -132642.4% net margin.
Peers · Healthcare
Connect Biopharma Holdings Limited25DOxford Investments Holdings Inc.——Real Brands, Inc.——Micro Imaging Technology, Inc.——Therma Bright Inc.23DGain Therapeutics, Inc.36DNeighbors
Montgomery →Key facts
CEOGarry A. Neil
SectorHealthcare
IndustryBiotechnology
HeadquartersRockville, MD
ExchangeNASDAQ: AVTX
Employees33
IPO date2015-10-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.